Lv21
140 积分 2024-09-02 加入
Safety, tolerability, pharmacokinetic, pharmacodynamic and immunogenicity profiles of Exendin‐4‐IgG4‐Fc in healthy subjects: A phase 1, single‐centre, randomized, double‐blind, dose escalation study
6小时前
已完结
A Phase 1 Pharmacokinetic Drug Interaction Study of Belumosudil Coadministered With CYP3A4 Inhibitors and Inducers and Proton Pump Inhibitors
5个月前
已完结
Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease
7个月前
已完结
Pathophysiology of Chronic Graft-versus-Host Disease and Therapeutic Targets
7个月前
已完结
Lecanemab in Early Alzheimer’s Disease
8个月前
已完结
Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study
8个月前
已完结
Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study
8个月前
已关闭
Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study
8个月前
已关闭
Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and Pegylated Interferon Alfa-2a in Patients With Chronic HBV Infection Naïve to Nucleos(t)ide Therapy
8个月前
已完结
Sequential Peg-IFN after bepirovirsen may reduce post-treatment relapse in chronic hepatitis B
8个月前
已完结
皖公网安备34019202002308
